232 related articles for article (PubMed ID: 33961431)
1. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
2. Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC
Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
[TBL] [Abstract][Full Text] [Related]
3. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SHP2 as an approach to block RAS-driven cancers.
Chou YT; Bivona TG
Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Taylor-Harding B; Aspuria PJ; Agadjanian H; Cheon DJ; Mizuno T; Greenberg D; Allen JR; Spurka L; Funari V; Spiteri E; Wang Q; Orsulic S; Walsh C; Karlan BY; Wiedemeyer WR
Oncotarget; 2015 Jan; 6(2):696-714. PubMed ID: 25557169
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets.
Pudewell S; Ahmadian MR
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208655
[TBL] [Abstract][Full Text] [Related]
7. An activating mutation in sos-1 identifies its Dbl domain as a critical inhibitor of the epidermal growth factor receptor pathway during Caenorhabditis elegans vulval development.
Modzelewska K; Elgort MG; Huang J; Jongeward G; Lauritzen A; Yoon CH; Sternberg PW; Moghal N
Mol Cell Biol; 2007 May; 27(10):3695-707. PubMed ID: 17339331
[TBL] [Abstract][Full Text] [Related]
8. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
9. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
10. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
Besset V; Scott RP; Ibáñez CF
J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
[TBL] [Abstract][Full Text] [Related]
11. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
[TBL] [Abstract][Full Text] [Related]
12. The Role of Wild-Type RAS in Oncogenic RAS Transformation.
Sheffels E; Kortum RL
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33924994
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAS oncogenesis with SOS1 inhibitors.
Hillig RC; Bader B
Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
15. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.
Tulpule A; Guan J; Neel DS; Allegakoen HR; Lin YP; Brown D; Chou YT; Heslin A; Chatterjee N; Perati S; Menon S; Nguyen TA; Debnath J; Ramirez AD; Shi X; Yang B; Feng S; Makhija S; Huang B; Bivona TG
Cell; 2021 May; 184(10):2649-2664.e18. PubMed ID: 33848463
[TBL] [Abstract][Full Text] [Related]
16. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of Oncogenic
Cai D; Choi PS; Gelbard M; Meyerson M
Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
[TBL] [Abstract][Full Text] [Related]
19. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
20. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.
Zhang Y; Kim J; Mueller AC; Dey B; Yang Y; Lee DH; Hachmann J; Finderle S; Park DM; Christensen J; Schiff D; Purow B; Dutta A; Abounader R
Cell Death Differ; 2014 May; 21(5):720-34. PubMed ID: 24440911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
